 BACKGROUND: Tumor M2-PK (Tu M2-PK) inactive dimeric form pyruvate kinase M2 proven elevated breast, lung, renal gastrointestinal malignancies. compared marker 26 patients metastatic thyroid carcinoma using established tumor marker thyroglobulin (Tg). MATERIALS METHODS: Plasma Tu M2-PK measured using ELISA assay (Schebo Biotech, Giessen, Germany) Tg measured serum using electrochemiluminescence Immunoassay (Tg Elecsys Systems, Roche, Germany), part routine follow-up patients. RESULTS: cut-off 15 U/ml, Tu M2-PK elevated 50% patients; cut-off 20 U/ml (grey zone 15-20 U/ml), Tu M2-PK elevated 27% patients. correlation coefficient serum Tg level Tu M2-PK -0.093. CONCLUSION: Tu M2-PK less valuable detection malignant thyroid disease Tg.